Skip to main content
main-content

06-06-2022 | ASCO 2022 | Conference coverage | Video

ATLANTIS rules out cabozantinib as a maintenance option for mUC

share
SHARE

Robert Jones explains why the ATLANTIS trial findings do not support the use of single-agent cabozantinib for the maintenance treatment of metastatic urothelial carcinoma, and what they mean for the role of VEGFR-targeted therapies in this tumor type (3:23).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany